In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses

Antiviral Research

Volumn 79, Issue 3, 2008, Pages 199-205

  Su, Ching Yao ^a,b   Wang, Shi Yun ^a   Shie, Jiun Jie ^a   Jeng, King Song ^c   Temperton, Nigel J ^d   Fang, Jim Min ^a,b   Wong, Chi Huey ^a,b   Cheng, Yih Shyun E ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Antiviral; Drug resistance; Neuraminidase inhibitor; Pseudotype virus; Viral release assay

Indexed keywords

2' (4 METHYLUMBELLIFERYL) ALPHA DEXTRO N ACETYLNEURAMINIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; GAG PROTEIN; HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; LUCIFERASE; N ACETYLNEURAMINIC ACID; PHOSPHONIC ACID DERIVATIVE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ARTICLE; ASSAY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC TRANSFECTION; IC 50; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS; LUCIFERASE GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOTYPE VIRUS; RETROVIRUS; VIRAL RELEASE ASSAY; VIRUS GENE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHICK EMBRYO; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENES, REPORTER; GENETIC ENGINEERING; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA, HUMAN; LEUKEMIA VIRUS, MURINE; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; VIRUS SHEDDING; ZANAMIVIR;

ORTHOMYXOVIRIDAE;

EID: 47049084460     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.03.002     Document Type: Article

References (32)

1. Abed Y., Goyette N., and Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9 (2004) 577-581
2. Alymova I.V., Taylor G., and Portner A. Neuraminidase inhibitors as antiviral agents. Curr. Drug Targets Infect. Disord. 5 (2005) 401-409
3. Bantia S., Ghate A.A., Ananth S.L., Babu Y.S., Air G.M., and Walsh G.M. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140. Antimicrob. Agents Chemother. 42 (1998) 801-807
4. Barman S., and Nayak D.P. Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J. Virol. 81 (2007) 12169-12178
5. Bhatia A., and Kast R.E. How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell. Mol. Biol. Lett. 12 (2007) 111-119
6. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., and Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal. Biochem. 280 (2000) 291-300
7. Cabezas J.A., Reglero A., and Hannoun C. A fluorometric procedure for measuring the neuraminidase activity: its application to the determination of this activity in influenza and parainfluenza viruses. Anal. Biochem. 131 (1983) 121-126
8. Cheam A.L., Barr I.G., Hampson A.W., Mosse J., and Hurt A.C. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antivir. Res. 63 (2004) 177-181
9. Chowell G., Miller M.A., and Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol. Infect. (2007) 1-13
10. De Clercq E. Antiviral agents active against influenza A viruses. Nature Rev. Drug Discov. 5 (2006) 1015-1025
11. França de Barros Jr. J., Sales Alviano D., da Silva M.H., Dutra Wigg M., Sales Alviano C., Schauer R., and dos Santos Silva Couceiro J.N. Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity. Intervirology 46 (2003) 199-206
12. Galarza J.M., Latham T., and Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18 (2005) 244-251
13. Gani R., Hughes H., Fleming D., Griffin T., Medlock J., and Leach S. Potential impact of antiviral drug use during influenza pandemic. Emerg. Infect. Dis. 11 (2005) 1355-1362
14. Guo C.T., Sun X.L., Kanie O., Shortridge K.F., Suzuki T., Miyamoto D., Hidari K.I., Wong C.H., and Suzuki Y. An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Glycobiology 12 (2002) 183-190
15. Hampson A.W. Avian influenza: a pandemic waiting in the wings?. Emerg. Med. Aust. 18 (2006) 420-429
16. Hurt A.C., Selleck P., Komadina N., Shaw R., Brown L., and Barr I.G. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antivir. Res. 73 (2007) 228-231
17. Katinger D., Mochalova L., Chinarev A., Bovin N., and Romanova J. Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates. Arch. Virol. 149 (2004) 2131-2140
18. Kiyotani K., Takei N., Senoo M., Takao S., Otsuki K., Tsubokura M., and Yoshida T. Enzymological characteristics of avian influenza A virus neuraminidase. Microbiol. Immunol. 31 (1987) 1131-1135
19. Kobasa D., Kodihalli S., Luo M., Castrucci M.R., Donatelli I., Suzuki Y., Suzuki T., and Kawaoka Y. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J. Virol. 73 (1999) 6743-6751
20. Kong W.P., Hood C., Yang Z.Y., Wei C.J., Xu L., Garcia-Sastre A., Tumpey T.M., and Nabel G.J. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 15987-15991
21. Li K.S., Guan Y., Wang J., Smith G.J., Xu K.M., Duan L., Rahardjo A.P., Puthavathana P., Buranathai C., Nguyen T.D., Estoepangestie A.T., Chaisingh A., Auewarakul P., Long H.T., Hanh N.T., Webby R.J., Poon L.L., Chen H., Shortridge K.F., Yuen K.Y., Webster R.G., and Peiris J.S. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 (2004) 209-213
22. Lin A.H., and Cannon P.M. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 83 (2002) 43-56
23. Liu H.L., Rong L.J., Zhou B., Wei J.C., Zheng Q.S., and Chen P.Y. Characterization of murine leukemia virus recombinants that express H5N1 subtype avian influenza virus hemagglutinin glycoproteins. Sheng Wu Gong Cheng Xue Bao 21 (2005) 47-51
24. Mishin V.P., Novikov D., Hayden F.G., and Gubareva L.V. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J. Virol. 79 (2005) 12416-12424
25. Molla A., Kati W., Carrick R., Steffy K., Shi Y., Montgomery D., Gusick N., Stoll V.S., Stewart K.D., Ng T.I., Maring C., Kempf D.J., and Kohlbrenner W. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor A-315675. J. Virol. 76 (2002) 5380-5386
26. Onodera S. A microplate assay for sialidase activity using plant lectin binding to N-acetyllactosamine. Biol. Pharm. Bull. 17 (1994) 29-33
27. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61 (1974) 397-410
28. Poland G.A., Jacobson R.M., and Targonski P.V. Avian and pandemic influenza: an overview. Vaccine 25 (2007) 3057-3061
29. Sato K., Hanagata G., Kiso M., Hasegawa A., and Suzuki Y. Specificity of the N1 and N2 sialidase subtypes of human influenza A virus for natural and synthetic gangliosides. Glycobiology 8 (1998) 527-532
30. Shie J.J., Fang J.M., Wang S.Y., Tsai K.C., Cheng Y.S., Yang A.S., Hsiao S.C., Su C.Y., and Wong C.H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J. Am. Chem. Soc. 129 (2007) 11892-11893
31. Temperton N.J., Hoschler K., Major D., Nicolson C., Manvell R., Hien V.M., Ha D.Q., de Jong M., Zambon M., Takeuchi Y., and Weiss R.A. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenz. Other Respir. Vir. 1 (2007) 105-112
32. Vila-Córcoles A., Rodriguez T., de Diego C., Ochoa O., Valdivieso A., Salsench E., Ansa X., Badia W., and Saún N. Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002-2005 influenza periods. Vaccine 25 (2007) 6699-6707